scispace - formally typeset
Search or ask a question
Topic

Teniposide

About: Teniposide is a research topic. Over the lifetime, 498 publications have been published within this topic receiving 18899 citations. The topic is also known as: isosulfan blue & VM-26.


Papers
More filters
01 Jan 1993
TL;DR: Although the modest activity seen was comparable to that of VP-16 (etoposide) as a single agent, the hematologic toxicity observed in this trial would likely preclude further trials of VM-26 (teniposide] in advanced gastric cancer.
Abstract: Summary The Southwest Oncology Group conducted a trial of VM-26 (teniposide) in patients with advanced gastric cancer. VM-26 60 mg/m 2 IV infusion over 30-45 minutes was given daily for 5 days every 21 days. Twentyone eligible patients with measurable disease and a SWOG performance status of 0-2 were analyzed for response and toxicity. Partial responses were seen in 2 of the 21 eligible patients (9.5 %). Median survival was 3.8 months. Severe or life-threatening toxicity was observed in 13/21 (62%) patients. This included two drug related deaths related to neutropenic sepsis and seven other patients with grade 4 granulocytopenia (< 500/mmJ). Liver dysfunction and hypotension were seen less often and were not dose limiting. Although the modest activity seen was comparable to that of VP-16 (etoposide) as a single agent, the hematologic toxicity observed in this trial would likely preclude further trials of VM-26 (teniposide) in advanced gastric cancer.

839 citations

Journal ArticleDOI
TL;DR: The risk of epipodophyllotoxin-related AML depends largely on the schedule of drug administration, and radiotherapy and the initial biologic features of the leukemic blast cells do not appear to have critical roles.
Abstract: Background and Methods. Treatment of cancer with the epipodophyllotoxins (etoposide and teniposide) has been linked to the development of acute myeloid leukemia (AML) in children and adults, but the factors that might influence the risk of this complication of therapy are poorly defined. We therefore assessed the importance of potential risk factors for secondary AML in 734 consecutive children with acute lymphoblastic leukemia who attained complete remission and received continuation (maintenance) treatment according to different schedules of epipodophyllotoxin administration. Results. Secondary AML was diagnosed in 21 of the 734 patients, in 17 of whom this complication was the initial adverse event. Prolonged administration of epipodophyllotoxin (teniposide with or without etoposide) twice weekly or weekly was independently associated with the development of secondary AML (P<0.01 by Cox regression analysis). The overall cumulative risk of AML at six years was 3.8 percent (95 percent confidence...

669 citations

Journal ArticleDOI
TL;DR: Adjusting the dose of methotrexate to account for the patient's ability to clear the drug can improve the outcome in children with B-lineage acute lymphoblastic leukemia.
Abstract: Background The rate of clearance of antileukemic agents differs by a factor of 3 to 10 among children with acute lymphoblastic leukemia. We hypothesized that the outcome of treatment would be improved if doses were individualized to prevent low systemic exposure to the drugs in patients with fast drug clearance. Methods We stratified and randomly assigned 182 children with newly diagnosed acute lymphoblastic leukemia to postremission regimens that included high-dose methotrexate and teniposide plus cytarabine. The doses of these drugs were based on body-surface area (in the conventional-therapy group) or the rates of clearance of the three medications in each patient (in the individualized-treatment group). In the individualized-treatment group, doses were increased in patients with rapid clearance and decreased in patients with very slow clearance. Results Patients who received individualized doses had significantly fewer courses of treatment with systemic exposures below the target range than did patien...

440 citations

Journal Article
TL;DR: The effects of topoisomerase II-reactive epipodophyllotoxins etoposide and teniposide as well as amsacrine on the viability of thymocytes in primary culture has been examined, indicating that topoisomersase II has a role in the very first stages of the process.
Abstract: The effects of topoisomerase II-reactive epipodophyllotoxins etoposide and teniposide as well as amsacrine on the viability of thymocytes in primary culture has been examined. All three drugs were shown to produce DNA cleavage detectable by resolving isolated DNA by pulsed field agarose gel electrophoresis. The DNA cleavage was found to have two components. The first was due to the interaction of the drugs with topoisomerase II, whereas the second component was due to endonuclease cleavage caused by the drug-induced entry of the thymocytes into programmed cell death or apoptosis. This second component of the DNA cleavage was also detected in thymocytes undergoing apoptosis following exposure to the glucocorticoid analogue, dexamethasone. The effect of the drugs on programmed cell death is dependent upon new protein and RNA synthesis, indicating that topoisomerase II has a role in the very first stages of the process. These results are discussed in terms of the use of this class of topoisomerase II-reactive drugs in chemotherapy.

406 citations

Journal ArticleDOI
TL;DR: This review deals with the historical discovery of particularly important lignan derivatives used in cancer chemotherapy, and it will be demonstrated how the activities and the ability of this class of compounds to inhibit topoisomerase II were discovered by different research teams.

333 citations


Network Information
Related Topics (5)
Metastasis
103.6K papers, 3.4M citations
71% related
Cancer
339.6K papers, 10.9M citations
71% related
Apoptosis
115.4K papers, 4.8M citations
70% related
Mutation
45.2K papers, 2.6M citations
70% related
Carcinogenesis
60.3K papers, 3.1M citations
69% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
20232
20224
20214
20206
20194
20185